Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

British Journal of Haematology

Volumn 174, Issue 6, 2016, Pages 859-867

  Martínez, Carmen ^a   Díaz López, Antonio ^b   Rodriguez Calvillo, Mercedes ^c   García Sanz, Ramón ^d   Terol, María José ^e   Pérez Ceballos, Elena ^f   Jiménez, Maria J ^g   Cantalapiedra, Alberto ^h   Domingo Domenech, Eva ⁱ   Rodriguez, María José ^j   Sampol, Antonia ^k   Espeso, Manuel ^l   López, Francisco Javier ^m   Briones, Javier ⁿ   García, Juan F ^b   Sureda, Anna ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL MORALES MESEGUER   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

ⁱ HOSPITAL DURAN I REYNALS   (Spain)

^j HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^k HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^l HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

ESHAP; Hodgkin lymphoma; ofatumumab; relapse; salvage therapy

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; OFATUMUMAB; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLASSICAL HODGKIN LYMPHOMA; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEPATITIS B; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 84986000547     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14133     Document Type: Article

References (33)

1. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A. & Armand, P. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine, 372, 311–319.
2. Aparicio, J., Segura, A., Garcera, S., Oltra, A., Santaballa, A., Yuste, A. & Pastor, M. (1999) ESHAP is an active regimen for relapsing Hodgkin's disease. Annals of Oncology, 10, 593–595.
3. Bartlett, N.L., Niedzwiecki, D., Johnson, J.L., Friedberg, J.W., Johnson, K.B., van Besien, K., Zelenetz, A.D., Cheson, B.D. & Canellos, G.P. (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology, 18, 1071–1079.
4. escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. Blood, 124, abst. 500
5. Cheson, B.D., Fisher, R.I., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579–586.
6. Clodi, K., Asgari, Z., Younes, M., Palmer, J.L., Cabanillas, F., Carbone, A., Andreeff, M. & Younes, A. (2002) Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer, 94, 1–5.
7. Cocorocchio, E., Peccatori, F., Vanazzi, A., Piperno, G., Calabrese, L., Botteri, E., Travaini, L., Preda, L. & Martinelli, G. (2013) High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Hematology Oncology, 31, 34–40.
8. Colwill, R., Crump, M., Couture, F., Anish, R., Stewart, A.K., Sutton, D.M., Scott, J.G., Sutcliffe, S.B., Brandwein, J.M. & Keating, A. (1995) Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. Journal of Clinical Oncology, 13, 396–402.
9. Eichenauer, D.A., Goergen, H., Plütschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, H., Halbsguth, T., Bröckelmann, P.J., Fuchs, M., Böll, B., von Tresckow, B., Bosrchmann, P. & Engert, A. (2015). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin Study Group. Leukemia, advanced online publication 11 December 2015. doi: 10.1038/leu.2015.321
10. Fehniger, T.A., Larson, S., Trinkaus, K., Siegel, M.J., Cashen, A.F., Blum, K.A., Fenske, T.S., Hurd, D.D., Goy, A., Schneider, S.E., Keppel, C.R., Wagner-Johnston, N.D., Carson, K.R. & Bartlett, N.L. (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood, 118, 5119–5125.
11. Fermé, C., Mounier, N., Divine, M., Brice, P., Stamatoullas, A., Reman, O., Voillat, L., Jaubert, J., Lederlin, P., Colin, P., Berger, F. & Salles, G. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of Clinical Oncology, 20, 467–475.
12. Fernandez de Larrea, C., Martinez, C., Gaya, A., López-Guillermo, A., Rovira, M., Fernández-Avilés, F., Lozano, M., Bosch, F., Esteve, J., Nomdedeu, B., Montserrat, E. & Carreras, E. (2010) Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. Annals of Oncology, 21, 1211–1216.
13. García-Sanz, R., Sureda, A., Alonso-Álvarez, S., Gonzalez, A.P., Rodriguez, A., Salar, A., de la Cruz, F., Domingo, E., Moreno, M., López, J., Piñana, J.L., Rodriguez, G., Canales, M., Gutierrez, A.M., López-Guillermo, A., Caballero, M.D., Jiménez, S. & Martínez, C. (2015) Evaluation of the régimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of lymphoma and bone marrow transplantation (GELTAMO). Blood, 126, abst. 582.
14. Johnston, P.B., Inwards, D.J., Colgan, J.P., Laplant, B.R., Kabat, B.F., Habermann, T.M., Micallef, I.N., Porrata, L.F., Ansell, S.M., Reeder, C.B., Roy, V. & Witzig, T.E. (2010) A phase II of the oral m-TOR inhibitor everolimus in relapsed Hodgkin lymhoma. American Journal of Hematology, 85, 320–324.
15. Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H.H., Dörken, B., Hossfeld, D.K., Diehl, V. & Engert, A. (2002) Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Annals of Oncology, 13, 1628–1635.
16. Kasamon, Y.L., Jacene, H.A., Gocke, C.D., Swinnen, L.J., Gladstone, D.E., Perkins, B., Link, B.K., Popplewell, L.L., Habermann, T.M., Herman, J.M., Matsui, W.H., Jones, R.J. & Ambinder, R.F. (2012) Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood, 119, 4129–4132.
17. Kim, S., Fridlender, Z.G., Dunn, R., Kehry, M.R., Kapoor, V., Blouin, A., Kaiser, L.R. & Albelda, S.M. (2008) B-cell depletion using anti-CD20 antobody augments anti-tumor immune responses and immunotherapy in non hematopoietic murine tumor models. Journal of Immunotherapy, 31, 446–457.
18. Kuruvilla, J., Keating, A. & Crump, M. (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood, 117, 4208–4217.
19. Labrador, J., Cabrero-Calvo, M., Pérez-López, E., Mateos, M.V., Vázquez, L., Caballero, M.D. & García-Sanz, R. (2014) ESHAP as salvage therapy for relapsed or refractory Hodgkin lymphoma. Annals of Hematology, 93, 1745–1753.
20. LaCasce, A.S., Bociek, G., Sawas, A., Caimi, P.F., Agura, E., Matous, J., Ansell, S., Crosswell, H., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O'Connor, O.A., Josephson, N. & Advani, R. (2015) Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood, 126, abst. 3982.
21. Moskowitz, A.J., Yahalom, J., Kewalramani, T., Maragulia, J.C., Vanak, J.M., Zelenetz, A.D. & Moskowitz, C.H. (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood, 116, 4934–4937.
22. Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., Nimer, S.D., Gerecitano, J., Hamlin, P., Horwitz, S., Moskowitz, A.J., Noy, A., Palomba, L., Perales, M.A., Portlock, C., Straus, D., Maragulia, J.C., Schoder, H. & Yahalom, J. (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 119, 1665–1670.
23. Moskowitz, A.J., Schöder, H., Yahalom, J., McCall, S.J., Fox, S.Y., Gerecitano, J., Grewal, R., Hamlin, P.A., Horwitz, S., Kobos, R., Kumar, A., Matasar, M., Noy, A., Palomba, M.L., Perales, M.A., Portlock, C.S., Sauter, C., Shukla, N., Steinherz, P., Straus, D., Trippett, T., Younes, A., Zelenetz, A. & Moskowitz, C. (2015) PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-center, phase 2 study. Lancet Oncology, 16, 284–292.
24. Oki, Y., Pro, B., Fayad, L.E., Romaguera, J., Samaniego, F., Hagemeister, F., Neelapu, S., McLaughlin, P., Goy, A. & Younes, A. (2008) Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer, 112, 831–836.
25. Puig, N., Pintilie, M., Seshadri, T., Al-Farsi, K., Nagy, T., Franke, N., Tsang, R., Keating, A., Crump, M. & Kuruvilla, J. (2010) Different response to salvage chemotherapy but similar posttransplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica, 95, 1496–1502.
26. Rassidakis, G.Z., Medeiros, L.J., Viviani, S., Bonfante, V., Nadali, G.P., Vassilakopoulos, T.P., Mesina, O., Herling, M., Angelopoulou, M.K., Giardini, R., Chilosi, M., Kittas, C., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Bonadonna, G., Gianni, A.M., Pizzolo, G., Pangalis, G.A., Cabanillas, F. & Sarris, A.H. (2002) CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Journal of Clinical Oncology, 20, 1278–1287.
27. Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., Nozza, A., Sarina, B., Morenghi, E., Castagna, L., Tirelli, U. & Balzarotti, M. (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 92, 35–41.
28. Sureda, A., Arranz, R., Iriondo, A., Carreras, E., Lahuerta, J.J., García-Conde, J., Jarque, I., Caballero, M.D., Ferrà, C., López, A., García-Laraña, J., Cabrera, R., Carrera, D., Ruiz-Romero, M.D., León, A., Rifón, J., Díaz-Mediavilla, J., Mataix, R., Morey, M., Moraleda, J.M., Altés, A., López-Guillermo, A., de la Serna, J., Fernández-Rañada, J.M., Sierra, J. & Conde, E. (2001) Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. Journal of Clinical Oncology, 19, 1395–1404.
29. Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G. & Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104, 1793–1800.
30. Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M.A., Fiumara, P., Goy, A., Jeha, S., Manning, J.T. Jr, Jones, D., Abruzzo, L.V. & Medeiros, L.J. (2002) A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer, 98, 310–314.
31. Younes, A., Oki, Y., McLaughlin, P., Copeland, A.R., Goy, A., Pro, B., Feng, L., Yuan, Y., Chuang, H.H., Macapinlac, H.A., Hagemeister, F., Romaguera, J., Samaniego, F., Fanale, M.A., Dabaja, B.S., Rodriguez, M.A., Dang, N., Kwak, L.W., Neelapu, S.S. & Fayad, L.E. (2012a) Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 119, 4123–4128.
32. Younes, A., Gopal, A.K., Smith, S., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Ramchandren, R., Bartlett, N.L., Cheson, B.D., de Vos, S., Forero-Torres, A., Moskowitz, C.H., Connors, J.M., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Chen, R. (2012b) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 30, 2183–2189.
33. Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P.L., Ong, T.C., Prince, H.M., Harrison, S.J., Kirschbaum, M., Johnston, P., Gallagher, J., Le Corre, C., Shen, A. & Engert, A. (2012c) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. Journal of Clinical Oncology, 30, 2197–2203.